Bicara Therapeutics Inc. Common Stock logo

Bicara Therapeutics Inc. Common Stock(BCAX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$10.02
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BCAX

11/13/2026: BCAX (1-star) is currently NOT-A-BUY. Pass it for now.

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibodies for oncology, anchored by its lead candidate ficerafusp alfa. The company's main strengths lie in its innovative scientific platform and targeted approach to hard-to-treat solid tumors like head and neck cancer. Its primary investment growth opportunity centers on upcoming clinical trial readouts and potential expansion into broader oncology indications. However, risks include a lack of commercial revenue, high R&D cash burn, and intense competition from large pharmaceutical incumbents. The stock suits high-risk growth investors willing to monitor clinical milestones and regulatory developments closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitOffers exposure to high-potential clinical-stage oncology innovation and pipeline expansion milestones.
Momentum investorStrong fit while signal remains positiveStock price is highly reactive to clinical trial catalysts, data readouts, and biotech sector sentiment swings.
Value investorWeak fitLacks current revenues, earnings, or traditional valuation metrics due to pre-commercial clinical status.
Dividend investorWeak fitThe company does not pay dividends and retains all cash for clinical development.
Low-risk investorWeak fitSubject to high binary clinical risks, regulatory uncertainty, and significant equity volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price swings around trial updates and market conditions.
Valuation riskHighValuation is heavily speculative, anchored on future clinical potential rather than trailing financial metrics.
Competition risk (oncology therapeutics)Medium / highThe company competes with heavily funded pharmaceutical giants dominating the cancer treatment landscape.
Business qualityMediumWhile backed by a robust scientific platform, the absence of approved commercial products limits current operational maturity.
Dividend incomeLow / noneNo cash returns are distributed to shareholders via dividends.
Execution riskHighSuccess relies entirely on successfully executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 665.20M USD
Price to earnings Ratio -
1Y Target Price 32.17
Price to earnings Ratio -
1Y Target Price 32.17
Volume (30-day avg) 1.8M shares
Beta -0.34
52 Weeks Range 7.87 - 30.99
Updated Date 11/15/2026
52 Weeks Range 7.87 - 30.99
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.46

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -39.03%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BCAX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
BCAX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-102.9%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
BCAX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
BCAX's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-102.9%, negative) and free-cash-flow growth (-43.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 102.1% and approximately 56.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 10.23% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 10.94%
T. Rowe Price Investment Management,Inc. 9.55%
Siren, L.L.C. 8.44%
Vestal Point Capital LP 7.91%
Deep Track Capital, LP 6.18%

Unit Economics (Per $1K Revenue)

★★★★★
BCAX generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.16% (Tax Credit)

Quantitative Style Profile

★★★★★
BCAX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesCurrently zero revenue as all therapeutic candidates remain in clinical development.The company is pre-revenue and depends on future drug approvals or partnerships to generate income.
Collaborations and LicensingPotential upfront fees, milestones, or royalties from strategic pharmaceutical collaborations.Partnerships can provide non-dilutive funding, though none form a core revenue stream at present.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 223.73M
Price to Sales(TTM) -
Enterprise Value 223.73M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 66.39M
Shares Floating 37.21M
Shares Outstanding 66.39M
Shares Floating 37.21M
Percent Insiders 10.23
Percent Institutions 102.09

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.